Sample rows from Vaccine Preventable Diseases. Field types are labelled in each column heading.
#	TextID	TextDisease Name	TextCategory	TextPrevalence	TextInheritance Pattern	TextAffected Gene(s)	LocationChromosome Location	TextKey Symptoms	TextTypical Age of Onset	TextDiagnosis Methods	TextAvailable Treatments	TextOrphan Drug Designation	TextICD-10 Code	NumberOMIM Number	TextAffected System	TextDisease Severity	TextLife Expectancy Impact
01	1	Measles (Rubeola)	Viral/Routine Childhood	~10.3 million cases and ~107,500 deaths globally (WHO/CDC, 2023); ~95,000 deaths in 2024; 57 countries had large outbreaks	Acquired (Measles morbillivirus, Paramyxoviridae)	N/A	N/A	High fever, cough, coryza, conjunctivitis, Koplik spots, cephalocaudal maculopapular rash; pneumonia, encephalitis	Any unvaccinated age (peak 1-4 yr)	Measles IgM serology, RT-PCR (NP/throat/urine), clinical case definition	Supportive care, vitamin A (2 doses WHO protocol), ribavirin (severe); M-M-R II (Merck), Priorix (GSK, US-licensed 2022), ProQuad/MMRV for prevention	No	B05.9	N/A	Multisystem (respiratory, skin, CNS)	Severe	Reduced (1-3/1000 case fatality in developed; up to 30% in malnourished)
02	2	Mumps	Viral/Routine Childhood	Sporadic outbreaks even in vaccinated populations	Acquired (Mumps orthorubulavirus, Paramyxoviridae)	N/A	N/A	Bilateral or unilateral parotitis, fever, malaise; orchitis, oophoritis, meningitis, deafness, pancreatitis	School-age children and young adults	RT-PCR from buccal swab, mumps IgM serology, clinical	Supportive care, NSAIDs, scrotal support; MMR/MMRV vaccine for prevention	No	B26.9	N/A	Salivary glands/multisystem	Moderate	Mostly normal; rare deaths from encephalitis
03	3	Rubella (German Measles)	Viral/Routine Childhood	~17,865 reported cases across 78 countries (WHO 2022); 97% decline since 2000; ~100,000 CRS infants/yr globally; 175/194 countries using rubella vaccine	Acquired (Rubella virus, Matonaviridae)	N/A	N/A	Mild low-grade fever, postauricular/suboccipital lymphadenopathy, fine pink maculopapular rash, arthralgia	Children and young adults	Rubella IgM serology, RT-PCR, IgG avidity	Supportive only; MMR (M-M-R II, Priorix) or MMRV (ProQuad); pre-pregnancy immunity check	No	B06.9	N/A	Multisystem (skin, joints, lymph nodes)	Mild	Normal in postnatal infection (devastating in fetus)
04	4	Poliomyelitis	Viral/Routine Childhood	WPV1 endemic in Pakistan/Afghanistan (62 WPV1 cases in 2024, ongoing 2025); cVDPV2 outbreaks in multiple countries	Acquired (Poliovirus types 1, 2, 3; Enterovirus C)	N/A	N/A	Asymptomatic (>70%), abortive (fever, sore throat), non-paralytic meningitis, or acute flaccid asymmetric paralysis; bulbar polio	Children <5 yr (mostly)	Stool culture x2, RT-PCR, intratypic differentiation, CSF analysis	Supportive only (no antiviral); IPV (IPOL, Sanofi), bOPV; nOPV2 (Bio Farma) WHO-prequalified Dec 2023 (~1.65 billion doses administered); rehabilitation	No	A80.9	N/A	CNS/anterior horn cells	Severe	Reduced (post-polio syndrome, respiratory failure)
05	5	Hepatitis A	Viral/Routine Childhood	~7,134 deaths globally (WHO, 2016 latest); ~90% of children infected by age 10 in high-endemicity areas (often subclinical)	Acquired (Hepatitis A virus, Picornaviridae)	N/A	N/A	Fever, malaise, anorexia, nausea, abdominal discomfort, jaundice, dark urine; rare fulminant hepatitis	Any age (children often asymptomatic)	Anti-HAV IgM serology, ALT/AST, total/direct bilirubin	Supportive care; Havrix (GSK), Vaqta (Merck), Twinrix (HepA+HepB combo, GSK), Avaxim (Sanofi); immune globulin post-exposure	No	B15.9	N/A	Liver	Variable	Normal (rarely fatal in adults >50 or chronic liver disease)

Vaccine Preventable Diseases

About this dataset

Data preview

Explore the sample

There’s more to discover.